Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer.

Rentsch CA, Cecchini MG, Thalmann GN.

Swiss Med Wkly. 2009 Apr 18;139(15-16):220-5. doi: smw-12284. Review.

2.

Role of Wnts in prostate cancer bone metastases.

Hall CL, Kang S, MacDougald OA, Keller ET.

J Cell Biochem. 2006 Mar 1;97(4):661-72. Review.

3.

Prostate cancer cells promote osteoblastic bone metastases through Wnts.

Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET.

Cancer Res. 2005 Sep 1;65(17):7554-60.

4.

Bone metastasis: histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations. A review.

Chappard D, Bouvard B, Baslé MF, Legrand E, Audran M.

Morphologie. 2011 Jun;95(309):65-75. doi: 10.1016/j.morpho.2011.02.004. Epub 2011 May 28. Review.

PMID:
21620753
5.

Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.

Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR.

J Bone Miner Res. 2005 Dec;20(12):2189-99. Epub 2005 Aug 1.

6.

When prostate cancer meets bone: control by wnts.

Emami KH, Corey E.

Cancer Lett. 2007 Aug 18;253(2):170-9. Epub 2007 Apr 25. Review.

PMID:
17462819
7.

Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.

Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET.

Cancer Res. 2005 Sep 15;65(18):8274-85.

8.

Pathogenesis of osteoblastic bone metastases from prostate cancer.

Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D.

Cancer. 2010 Mar 15;116(6):1406-18. doi: 10.1002/cncr.24896. Review. Erratum in: Cancer. 2010 May 15;116(10):2503.

9.

Mechanisms of tumor metastasis to the bone: challenges and opportunities.

Reddi AH, Roodman D, Freeman C, Mohla S.

J Bone Miner Res. 2003 Feb;18(2):190-4. Review.

10.

Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.

Vessella RL, Corey E.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6285s-6290s. Review.

11.

Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.

Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nör J, McCauley LK, Taichman RS, Keller ET.

Cancer Res. 2004 Feb 1;64(3):994-9.

12.

Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.

Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM.

Oncogene. 2008 Jan 24;27(5):596-603. Epub 2007 Aug 13.

PMID:
17700537
13.

Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis?

Buijs JT, Petersen M, van der Horst G, van der Pluijm G.

Curr Pharm Des. 2010;16(11):1291-300. Review.

PMID:
20166979
14.

The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis.

Secondini C, Wetterwald A, Schwaninger R, Thalmann GN, Cecchini MG.

PLoS One. 2011 Jan 13;6(1):e16078. doi: 10.1371/journal.pone.0016078.

15.

Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.

Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC.

Br J Cancer. 1998 Nov;78(9):1219-23.

16.

[Pathophysiology of bone metastases].

Chappard D, Legrand E, Massin P, Basle MF, Audran M.

Prog Urol. 2003 Apr;13(2 Suppl 1):9-17. Review. French.

PMID:
12815804
17.

Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.

Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, Yamanaka H.

Prostate. 2003 Mar 1;54(4):268-74.

PMID:
12539225
18.

Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review).

Ye L, Kynaston HG, Jiang WG.

Int J Mol Med. 2007 Jul;20(1):103-11. Review.

PMID:
17549396
19.

Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.

Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH.

Cancer Res. 2004 Nov 15;64(22):8276-84.

20.

Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.

Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR.

Bone. 2006 Feb;38(2):154-66. Epub 2005 Aug 26.

PMID:
16126463

Supplemental Content

Support Center